Society for Translational Oncology

starstarstarstarstar

Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist.
www.sto-online.org TheOncologist.com

Podcasts.com RSS Feed URL

Society for Translational Oncology navigateright Episode

IDH Inhibition in Acute Myeloid Leukemia – Emergence of a New Therapeutic Era

2HG, elevated in patients with IDH mutations, can also be measured in the serum and urine of affected patients, where it can serve as a biomarker of disease activity and therapeutic response. These advances triggered development of a new class of small molecule inhibitors of mutant IDH enzymes. After demonstrating promising anti-leukemic activity in animal models, phase 1 and 2 clinical trials of IDH inhibitors followed.  Trials of the IDH1 inhibitor ivosidenib and the IDH2 inhibitor enasidenib demonstrated single agent activity, response rate, transfusion independence, and long-term outcomes.

Video Overview: https://youtu.be/WTX_WqOz5q8

Amir Fathi, MD 

MGH/Harvard Medical School

STO gratefully acknowledges educational grants in partial support of this activity from:
Agios Pharmaceuticals
Amgen
Celgene Corporation
Novartis Pharmaceuticals Corp.
Pfizer Inc.